Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,597 across all filing types
Latest filing 2014-08-13 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
公司章程（2014年8月）
Governance Information Classification · 100% confidence The document is titled "广东台城制药股份有限公司 章程" which translates to "Articles of Association" or "Company Bylaws" of Guangdong Taicheng Pharmaceutical Co., Ltd. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other governance-related rules. There is no indication of financial data, audit results, earnings, or any report publication. The content is focused on the internal rules and governance framework of the company. Therefore, this document fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, confirming it is not a mere announcement or summary but the actual governance document.
2014-08-13 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding abnormal stock trading fluctuations for Guangdong Taicheng Pharmaceutical Co., Ltd. It discusses stock turnover rates, confirms no undisclosed material information, and provides risk warnings to investors. The text does not contain financial statements, detailed financial results, or management discussion of financial performance. It is a regulatory disclosure related to stock trading activity and risk notification, typical of a regulatory filing to comply with stock exchange rules. The document length is 3571 characters, relatively short, and it is an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS).
2014-08-12 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is titled '股票交易异常波动公告' which translates to 'Announcement of Abnormal Stock Trading Fluctuations'. It discusses the stock price movements over two days exceeding 20%, the company's verification of no undisclosed material information, risk factors related to the company's business and stock, and a reminder to investors about risks. There are no financial statements, no detailed financial performance data, no management discussion of results, nor any indication that this is a report or presentation. The document is a regulatory announcement related to stock price abnormality and risk disclosure, typical of a regulatory filing to comply with stock exchange rules. The document length is 3257 characters, relatively short, and it is an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS).
2014-08-07 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding abnormal stock price fluctuations for Guangdong Taicheng Pharmaceutical Co., Ltd. It details the stock price movements over specific dates, confirms no undisclosed material information exists, and provides risk warnings related to the company's business and industry environment. The document is relatively short (3,254 characters) and serves as a regulatory disclosure about stock trading anomalies rather than a financial report or earnings release. It does not contain financial statements, management discussion, or detailed financial data. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2014-08-05 Chinese
上市首日风险提示公告
Regulatory Filings Classification · 95% confidence The document is a risk warning announcement related to the company's stock listing on the Shenzhen Stock Exchange. It includes detailed risk factors about the company's business, product quality, market risks, and regulatory environment. The document is relatively short (2945 characters) and does not contain financial statements or detailed financial data. It is not an annual or interim report, nor is it a certification or voting result. It is a regulatory announcement informing investors about risks associated with the company's listing and operations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2014-07-30 Chinese
国浩律师（深圳）事务所关于公司首次公开发行的股票于深圳证券交易所上市的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the initial public offering (IPO) and listing of Guangdong Taicheng Pharmaceutical Co., Ltd. on the Shenzhen Stock Exchange. It discusses the legal compliance, approvals, and qualifications related to the company's IPO and listing process. The document is not a financial report, earnings release, or management discussion, but a legal opinion supporting the IPO listing. It is a specialized legal document related to capital market activities, specifically the company's initial public offering and stock listing. This type of document fits best under the category of Capital/Financing Update (CAP), as it pertains to the company's fundraising and capital market listing activities. The document length is under 5,000 characters, but it is not merely an announcement of a report publication; it is the legal opinion itself. Therefore, the appropriate classification is CAP with high confidence.
2014-07-29 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.